Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.64 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | PGK1 | P00558 | 1/20 | 0.57 |
| ▸ | PGK2 | P07205 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8423342 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL8426428 | 0.93 | ADORA3 (0.63) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL8426439 | 0.93 | ADORA3 (0.63) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL8422649 | 0.92 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL8422643 | 0.92 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL8426311 | 0.91 | ADORA3 (0.60) | ADORA3ADORA1SLC29A1PGK1PGK2 | |
| SCHEMBL8426308 | 0.91 | ADORA3 (0.60) | ADORA3ADORA1SLC29A1PGK1PGK2 | |
| SCHEMBL18660509 | 0.90 | ADORA3 (0.69) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL8426477 | 0.90 | P2RY12 (0.60) | ADORA3ADORA1ADORA2AADORA2BPGK1 | |
| SCHEMBL8780661 | 0.90 | P2RY12 (0.60) | ADORA3ADORA1ADORA2AADORA2BPGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241606-A1 | Process for preparation of cangrelor tetrasodium and intermediate therefor | SCINOPHARM TAIWAN, LTD. | 2019-08-08 | — | — | US | disclosed |
| US-20190241606-A1 | Process for preparation of cangrelor tetrasodium and intermediate therefor | SCINOPHARM TAIWAN, LTD. | 2019-08-08 | — | — | US | disclosed |
| WO-2019151941-A1 | PROCESS FOR PREPARATION OF CANGRELOR TETRASODIUM AND INTERMEDIATE THEREFOR | SCINOPHARM TAIWAN LTD. (TW) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019151941-A1 | PROCESS FOR PREPARATION OF CANGRELOR TETRASODIUM AND INTERMEDIATE THEREFOR | SCINOPHARM TAIWAN LTD. (TW) | 2019-08-08 | — | — | WO | disclosed |
| US-5955447-A | ADMINISTERING AS ANTICOAGULANT; TREATING CARDIOVASCULAR DISORDERS | ASTRA PHARMACEUTICALS LIMITED (GB) | 1999-09-21 | — | — | US | disclosed |
| US-5721219-A | ANTICOAGULANTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-02-24 | — | — | US | disclosed |
| EP-0683789-B1 | N-ALKYL-2-SUBSTITUTED ATP ANALOGUES | ASTRA PHARMA PROD (GB) | 1997-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241606-A1 | Process for preparation of cangrelor tetrasodium and intermediate therefor | ASGR1, SUCNR1, FAR1 | ADORA3 734/4885ADORA1 102/4885ADORA2A 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.